Localized Prostate Cancer COE

Universal Germline Genetic Testing for Prostate Cancer Patients - Neal Shore & Sarah Young

Details
Neal Shore and Sarah Young join Zachary Klaassen to discuss a JCO Oncology Practice publication advocating for universal germline genetic testing in prostate cancer patients. The discussion highlights that 8-14% of unselected prostate cancer patients carry pathogenic variants, with clinical utility across all disease stages from early detection to treatment selection. Despite the proven benefits f...

Overtreatment of Prostate Cancer Persists in Men with Limited Life Expectancy - Timothy Daskivich

Details
Zachary Klaassen hosts Timothy Daskivich to discuss a JAMA Internal Medicine publication on prostate cancer overtreatment among men with limited longevity in the active surveillance era. The conversation examines findings from a study of 243,000 VA patients that reveals increasing rates of definitive treatment for intermediate and high-risk prostate cancer among men with limited life expectancy, d...

AI-Derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer - Martin King & David Yang

Details
Martin King and David Yang join Zachary Klaassen to discuss their study on AI-derived tumor volume assessment in prostate cancer MRI. The research demonstrates how their AI model successfully segments and measures prostate tumors from MRI images, showing strong prognostic value for cancer outcomes in both radiation and surgery patients. The study reveals that AI-derived tumor volume serves as an i...

CLARIFY Trial: Multiday 64Cu-SAR-bisPSMA PET Scans Refine Prostate Cancer Assessment - Luke Nordquist

Details
Zachary Klaassen and Luke Nordquist discuss the CLARIFY trial, which evaluates a novel Copper-64 SAR-bisPSMA PET imaging technique for high-risk prostate cancer patients before surgery. Dr. Nordquist explains the trial's focus on patients with aggressive disease features who are scheduled for surgery within 90 days, highlighting the advantage of Copper-64's longer half-life which allows for imagin...

'Unfavorable Histology’ Classification Aims to Reduce Unnecessary Treatment, Discussion

Details
An engaging Q&A session follows Matthew Cooperberg's discussion with pathologists Jesse McKenney and Jane Nguyen about their prostate cancer histology classification system. The conversation explores how this new approach might interface with emerging AI technologies and genomic tests like Decipher, while addressing practical questions about implementation and accessibility. The experts clarify th...

'Unfavorable Histology’ Classification Aims to Reduce Unnecessary Treatment, Journal Club - Jesse McKenney, Jane Nguyen, & Cornelia Ding

Details
Matthew Cooperberg hosts a discussion with Jesse McKenney and Jane Nguyen about research on prostate cancer grading, presented in a paper proposing a new definition of adverse pathology. Dr. McKenney details how their work challenges traditional Gleason grading systems by introducing a simplified "favorable" versus "unfavorable" histology classification, primarily based on cribriform patterns in t...

Pelvic Muscle Rehabilitation after Radical Prostatectomy - Diane Newman

Details
Diane Newman delivers a presentation on pelvic floor muscle rehabilitation following radical prostatectomy, highlighting the prevalence and impact of post-surgical urinary incontinence. She explained that while incontinence initially affects 2-90% of patients, most improve within 2-3 months, though 5-20% may experience ongoing symptoms beyond two years. Newman emphasized the importance of pre- and...

Integrating Genomic Testing with MRI Enhances Stratification of Surveillance Patients - Eric Kim & Mark Sultan

Details
Mark Sultan and Eric Kim discuss research on predicting prostate cancer progression during active surveillance using Decipher® genomic classifier scores and MRI characteristics. Their study reveals that while both high Decipher® scores and high-risk MRI findings independently predict progression, these markers are weakly correlated, suggesting they capture distinct risk information. The conversati...

Traction Therapy Helps Men Regain Penile Length After Prostate Cancer Treatment - Amy Pearlman

Details
Amy Pearlman discusses penile traction therapy using the RestoreX device, a second-generation technology designed to address penile length changes after prostate cancer treatment. Dr. Pearlman explains how this device, developed by Dr. Landon Trost at Mayo Clinic, offers advantages over first-generation devices through its dynamic stretching capabilities and shorter required usage times. The discu...

Penile Rehabilitation After Prostate Cancer Treatment - Amy Pearlman

Details
Amy Pearlman discusses penile rehabilitation strategies following prostate cancer treatment. Dr. Pearlman shares her expertise on vacuum pump therapy as a crucial component of penile rehabilitation. The discussion emphasizes the importance of early intervention and ongoing maintenance to preserve penile health, comparing the penis to a sponge that requires regular blood flow to maintain its struct...